Evidence map›Paper›PMID 33014206›Full record

ArticleCurrent therapeutic research, clinical and experimental2020

Impact of

Ken-Ichi Okada, Manabu Kawai, Seiko Hirono, Motoki Miyazawa, Yuji Kitahata, Ryohei Kobayashi, Masaki Ueno, Shinya Hayami, Toshio Shimokawa, Hiroki Yamaue

Open access · goldAbstract read
In one paragraph

Article in Current therapeutic research, clinical and experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ken-Ichi OkadaSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Manabu KawaiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Seiko HironoSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Motoki MiyazawaSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Yuji KitahataSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Ryohei KobayashiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Masaki UenoSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Shinya HayamiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Hiroki YamaueSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

objectivesThis prospective exploratory trial evaluates the efficacy of

methodsWe compared data from this interventional trial with a prior observational trial without administration of

resultsThreshold mean of Functional Assessment of Chronic Illness Therapy-Fatigue score across 8 weeks during chemotherapy was under 5.3 (

conclusions

Indexed as

FatigueJapanese herbal medicineNab-paclitaxel plus gemcitabineNinjin'yoeitoSupportive therapy

Identifiers

PMID33014206
PMCPMC7522496
OpenAlexW3087718459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.